At James Cowper Kreston we have significant experience of working with life science companies at all stages of their journey – from spin-out to IPO. We understand their needs and tailor our services to ensure that we work with their management teams to optimise their financial governance.
Such companies will be typically far longer pre-revenue than other technology based companies; they will have significant third party investment over a number of milestone linked rounds; they may have opportunities for collaborations/joint ventures and the trajectory for growth can be rapid – but equally the fortunes of such companies can change overnight. Because of the regulatory environment in which they operate they need advisers who can be flexible to support the business whatever is happening and at all stages of their lifecycle can ensure that the company’s governance is of high quality.